Telo Genomics Corp (TSE:TELO) has released an update.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Telo Genomics Corp has revealed promising results for its TeloViewSMM prognostic test, which outperformed existing models in identifying high and low-risk smoldering myeloma patients. This innovative test could transform patient management by offering a non-invasive method to monitor disease progression, addressing a significant market opportunity.
For further insights into TSE:TELO stock, check out TipRanks’ Stock Analysis page.